272 related articles for article (PubMed ID: 16047147)
1. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations.
DeGregorio MW; Dingley KH; Wurz GT; Ubick E; Turteltaub KW
Cancer Chemother Pharmacol; 2006 Feb; 57(3):335-42. PubMed ID: 16047147
[TBL] [Abstract][Full Text] [Related]
2. [Detecting doxorubicin concentration in KBv200 and KB cell xenografts in nude mice by high-performance liquid chromatography].
Deng WJ; Zeng ZL; Liang YJ; Dai CL; Zhang JY; Fu LW
Ai Zheng; 2008 Apr; 27(4):364-8. PubMed ID: 18423121
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor.
Lee ES; Na K; Bae YH
J Control Release; 2005 Mar; 103(2):405-18. PubMed ID: 15763623
[TBL] [Abstract][Full Text] [Related]
4. A simple HPLC method for doxorubicin in plasma and tissues of nude mice.
Al-Abd AM; Kim NH; Song SC; Lee SJ; Kuh HJ
Arch Pharm Res; 2009 Apr; 32(4):605-11. PubMed ID: 19407979
[TBL] [Abstract][Full Text] [Related]
5. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
6. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
Zhou PH; Yao LQ; Qin XY; Shen XZ; Liu YS; Lu WY; Yao M
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2073-6. PubMed ID: 14703420
[TBL] [Abstract][Full Text] [Related]
7. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.
Ponce AM; Viglianti BL; Yu D; Yarmolenko PS; Michelich CR; Woo J; Bally MB; Dewhirst MW
J Natl Cancer Inst; 2007 Jan; 99(1):53-63. PubMed ID: 17202113
[TBL] [Abstract][Full Text] [Related]
10. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method.
Lecároz C; Campanero MA; Gamazo C; Blanco-Prieto MJ
J Antimicrob Chemother; 2006 Sep; 58(3):557-63. PubMed ID: 16787953
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
12. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
13. Accelerator mass spectrometry of small biological samples.
Salehpour M; Forsgard N; Possnert G
Rapid Commun Mass Spectrom; 2008 Dec; 22(23):3928-34. PubMed ID: 18980253
[TBL] [Abstract][Full Text] [Related]
14. Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes.
Pan H; Han L; Chen W; Yao M; Lu W
J Control Release; 2008 Feb; 125(3):228-35. PubMed ID: 18022270
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.
Barpe DR; Rosa DD; Froehlich PE
Eur J Pharm Sci; 2010 Nov; 41(3-4):458-63. PubMed ID: 20688160
[TBL] [Abstract][Full Text] [Related]
17. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
18. In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.
Cheung RY; Rauth AM; Ronaldson PT; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2006 Apr; 62(3):321-31. PubMed ID: 16330194
[TBL] [Abstract][Full Text] [Related]
19. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
Ogawara K; Un K; Tanaka K; Higaki K; Kimura T
J Control Release; 2009 Jan; 133(1):4-10. PubMed ID: 18840484
[TBL] [Abstract][Full Text] [Related]
20. Cold protection and heat enhancement of doxorubicin skin toxicity in the mouse.
Dorr RT; Alberts DS; Stone A
Cancer Treat Rep; 1985 Apr; 69(4):431-7. PubMed ID: 3995512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]